The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 03, 2015
Filed:
Apr. 20, 2010
Applicants:
Jean-paul Castaigne, Mont-Royal, CA;
Michel Demeule, Beaconsfield, CA;
Betty Lawrence, Bolton, CA;
Inventors:
Assignee:
Angiochem, Inc., Montreal, CA;
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/04 (2006.01); A61K 31/70 (2006.01); A61K 31/337 (2006.01); A61K 31/475 (2006.01); A61K 31/704 (2006.01); A61K 38/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/70 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/704 (2013.01); A61K 38/10 (2013.01);
Abstract
Ovarian cancer is treated with conjugates of an anticancer agent and an Angiopep-2 polypeptide analog (i.e. a polypeptide comprising an amino acid sequence at least 80% identical to Seq. ID NO:97). Such treatment includes utility in treating metastatic ovarian cancer and in treating patients who have previously exhibited resistance to standard chemotherapeutic agents. Preferred anticancer agents include taxanes while the preferred conjugate is ANG1005, a conjugate comprising three molecules of paclitaxel conjugated to the peptide Angiopep-2.